News Alzheimer’s disease: FDA approves lecanemab amid cost and safety concerns BMJ 2023; 380 doi: https://doi.org/10.1136/bmj.p73 (Published 11 January 2023) Cite this as: BMJ 2023;380:p73 Article Related content Metrics Responses Peer review Related articles News FDA approves controversial Alzheimer’s drug despite uncertainty over effectiveness Published: 08 June 2021; BMJ 373 doi:10.1136/bmj.n1462 News Aduhelm: Approval of Alzheimer’s drug was highly unorthodox, finds report Published: 03 January 2023; BMJ 380 doi:10.1136/bmj.p6 News Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain Published: 01 December 2022; BMJ 379 doi:10.1136/bmj.o2912 News FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway Published: 30 July 2021; BMJ 374 doi:10.1136/bmj.n1898 News Alzheimer’s disease: Lecanemab gets full FDA approval and black box safety warning Published: 07 July 2023; BMJ 382 doi:10.1136/bmj.p1580 See more Semaglutide’s CVD indication could cost US Medicare $145bn extra a year BMJ August 28, 2024, 386 q1878; DOI: https://doi.org/10.1136/bmj.q1878 Semaglutide: UK regulator approves drug for prevention of cardiovascular events BMJ July 25, 2024, 386 q1660; DOI: https://doi.org/10.1136/bmj.q1660 Why India is failing to track heatstroke fatalities properly BMJ July 17, 2024, 386 q1437; DOI: https://doi.org/10.1136/bmj.q1437 Mail on Sunday articles that accused three commentators of being “statin deniers” were misinformed, judge rules BMJ June 26, 2024, 385 q1424; DOI: https://doi.org/10.1136/bmj.q1424 Sixty seconds on . . . flying BMJ June 10, 2024, 385 q1266; DOI: https://doi.org/10.1136/bmj.q1266 Cited by... Alzheimers disease: Lecanemab gets full FDA approval and black box safety warningFulltext PDF Estimated Effects of Amyloid Reduction on Cognitive Change: A Bayesian Update across a Range of PriorsFulltext PDF
